Methylene blue for septic shock in oncologic patients: A propensity score-matched cohort
Main findingResult — go to the resultRelative risk 0.80 95% CI 0.66–0.97Authors' conclusion
In oncologic patients with septic shock requiring multiple vasopressors, MB use was associated with lower 30-day mortality; however, within the limitations of this retrospective study, these findings should be interpreted cautiously.
Study context
- Population
- Adult oncologic patients with septic shock requiring multiple vasopressors (norepinephrine plus vasopressin or epinephrine), 2015–2025262 matched pairs analysed
- Participants
- 266 vs 10,163
- Exposure
- Methylene blue (MB) vs no MB
- MBn = 266
- Controlsn = 10,163reference
- Outcome
- All-cause mortality
- Follow-up
- 30 days
Methodological detailspropensity score-matched (1:1), TriNetX Research Network
- Propensity score-matched (1:1)
- TriNetX Research Network
Main finding
As reported in the abstract
Relative risk
0.80
95% CI 0.66–0.97
MB vs Controls
RR 0.80 (95% CI 0.66–0.97)
Observational data: associations, not effects.
Secondary outcomes
Acute kidney injury (AKI) and vasopressor escalation · 7 days
- Favorable associations with MB
Invasive mechanical ventilation · 7 days
- Did not differ between groups
Original publication
Methylene blue for septic shock in oncologic patients: A propensity score-matched cohort. J Crit Care. Published 3 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →